Comparing cough medicines for people with lung scarring and chronic cough
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This study tests two cough-relief medicines, gabapentin and benzonatate, against usual care in people with interstitial lung disease (lung scarring) who have had a chronic cough for at least 8 weeks. It aims to see which option works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of interstitial lung disease (lung scarring)
- You have had a cough for at least 8 weeks and rate its severity as 4 or higher on a 0–10 scale
- You have been on a stable treatment plan for your lung condition for at least 8 weeks
- You have not had a recent lung infection or flare-up requiring hospitalization in the past 8 weeks
- You have not used gabapentin or benzonatate in the past 4 weeks
- You do not have certain other conditions like severe heart failure, kidney or liver problems, or long-term oxygen therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether two different doses of duloxetine and amitriptyline can reduce coughing caused by interstitial lung disease (ILD). If you have had a long-lasting ILD-related cough despite stable ILD treatment, this trial may help find a better way to control your cough.
This trial is testing a telehealth program (using phone calls or video meetings) to help people with interstitial lung disease manage chronic cough. If you join, you'll get guidance and support to improve your cough symptoms and quality of life.
This trial tests whether a combination of two medications (dexamethasone and N-acetyl cysteine) can reduce breathing problems caused by radiation to lung tumors in patients who have both lung cancer and fibrotic interstitial lung disease (ILD). It aims to find a better way to manage side effects from radiation.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This study tests whether a combination of three medicines (azithromycin, hydroxychloroquine, and prednisone) can help people with scarring or inflammation in the lungs caused by certain genetic changes. It aims to see if these drugs can slow down or improve the lung disease.
This study uses analysis of mucus (sputum) to guide treatment with the goal of reducing long-lasting cough in adults with interstitial lung disease (ILD). You may be asked to provide sputum samples and may receive treatment decisions based on those results.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.